EU recommends Parkinson’s drug for approval

The first new drug in 10 years for Parkinson’s disease has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP). If the European commission follows this recommendation, then Xadago (safinamide), made by Italian firms Newron and Zambon, will be available to patients with mid to late stage Parkinson’s as an add-on to existing therapies.

The drug works by both inhibiting monoamine oxidase B (which degrades dopamine and is often overexpressed in Parkinson’s), and by blocking sodium channels that inhibit glutamate release (which are implicated in dyskinesia – the loss of fine motor control).

However, central nervous system diseases remain particularly tricky to develop drugs for, as shown by the latest clinical failure of an antibody treatment for Alzheimer’s disease. Roche has discontinued a Phase III trial of gantenerumab as it proved ineffective at preventing disease progression.

Related Content

Pills, prices and politics

17 December 2015 Business

news image

2015 saw the pharmaceutical industry clash with lawmakers

Business roundup

24 February 2011 Business

news image

Industry news, March 2011

Most Commented

Ethanol to butanol conversion shows sustainable potential

13 January 2016 Research

news image

Borrowed hydrogen chemistry drives reaction to obtain useful fuel from biomass

Injectable foam repairs bones

22 December 2015 Research

news image

Scientists say biomaterial could treat bone defects and diseases